Pfizer Halts Drug Trial, Investors Flee Axovant
Insights - When is a competing drug’s failure not a good thing? When your drug has the same mechanism of action.
Read nowMust Read
Obesity & PD-1: History Doesn’t Repeat But It Rhymes
The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical Submits 510(k) for Insulin Patch Pump
Modular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumLatest Posts
Trillium Grabs Some New Assets, But Remains a CD-47 Story; And, Some Updates
Research - Equities remain linked at the hip to the fluctuations in oil, and Thursday marked the first meaningful decoupling in the last month. According to the Wall Street Journal, over the past 20 trading days (one month) the correlation has been 0.97, the highest in 26 years.
Premium
Year of the Bear? A Webinar
Education - Oil has yet to stabilize and investors are skittish about a rising interest rate environment; it's the first since 2004. China's economy is slowing, and their markets have tanked over the last few months. These are why equities can't find a bottom, according to the financial press, anyway.
Premium
Shellacked: That’s The Word
Insights - How else to describe equity markets this year? The S&P 500, DOW, and NASDAQ have all returned below their 50-day and 200-day moving averages in … Continue Reading
Read now
Biotech’s Route Continues
Research - Today marked day two of the JP Morgan Healthcare investing conference, and biotech stocks still couldn’t catch a bid until late this afternoon. The mood … Continue Reading
Premium
UniQure’s On To Something in Hemophilia B
Research - UniQure’s (QURE) AAV5-enabled AMT-060 looks good in its first human testing to date, with four of five Hemophilia B patients in the low-dose cohort fully … Continue Reading
Read now
Stocks Start the New Year on the Wrong Foot
Insights - Biopharma stocks are starting the year off on absolutely the wrong foot (though so is everything else), and last night’s SEVEN secondary stock offerings didn’t help Wednesday's price action.
Premium